Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:48:05 EDT Thu 18 Apr 2024
Enter Symbol
or Name
USA
CA



Q:TLSA - TIZIANA LIFE SCIENCES LTD - https://www.tizianalifesciences.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TLSA - Q0.70.64·0.64796.40.64+0.120923.31,555.68592,1910.5944  0.82  0.491.3928  0.4119:45:4607:0015 min RT 2¢

Recent Trades - Last 10 of 2191
Time ETExPriceChangeVolume
19:45:46Q0.64780.1348100
19:40:16Q0.64480.1318697
19:34:37Q0.64480.131850
19:30:56Q0.64480.1318100
19:14:30Q0.64470.13175
19:10:26Q0.64480.131853
18:54:37Q0.64470.131715
18:49:16Q0.64470.131714
18:25:10Q0.64480.1318100
18:17:02Q0.64470.131726

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-18 07:00U:TLSANews ReleaseTiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
2024-04-11 07:00U:TLSANews ReleaseTiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
2024-03-05 07:00U:TLSANews ReleaseTiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Disease
2024-01-08 07:00U:TLSANews ReleaseTiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
2024-01-05 09:30U:TLSANews ReleaseTiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
2024-01-05 07:00U:TLSANews ReleaseTiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
2023-12-19 07:00U:TLSANews ReleaseTiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
2023-12-04 07:10U:TLSANews ReleaseTiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
2023-11-30 07:00U:TLSANews ReleaseTiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
2023-11-01 07:00U:TLSANews ReleaseTiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023
2023-10-18 07:00U:TLSANews ReleaseTiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
2023-10-17 03:29U:TLSANews ReleaseTiziana Life Sciences reveals "exciting" clinical data from latest MS trial
2023-10-16 08:01U:TLSANews ReleaseTiziana Life Sciences reports six-month PET scan results for MS patients
2023-10-16 07:00U:TLSANews ReleaseTiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
2023-10-13 07:00U:TLSANews ReleaseTiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
2023-10-11 07:00U:TLSANews ReleaseTiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
2023-09-26 07:00U:TLSANews ReleaseTiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
2023-09-12 08:21U:TLSANews ReleaseTiziana Life Sciences' Alzheimer's treatment validated in new study
2023-09-08 07:00U:TLSANews ReleaseTiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
2023-09-06 07:00U:TLSANews ReleaseStudy Validating MoA of Intranasal Foralumab in Alzheimer ¢ € ™s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance